Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy

Abstract

Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatment in breast cancer patients, particularly during aromatase-inhibitors therapy. Due to estrogens contra-indication, proper therapy for such symptom remains often an inadequately addressed clinical problem. After an accurate assessment of the risk/benefit ratio, vaginal low-dose estrogen treatment (better with estriol) may have a role in controlling vaginal atrophy in selected and informed breast cancer women.

Keywords::

• Breast cancer survivors
• menopause treatment-related
• tamoxifen and aromatase inhibitors therapy
• vaginal estrogen therapy

Declaration of Interest: The authors report no conflicts of interest.

Notice of Correction

The version of this article published online ahead of print on 21 Sep 2012 contained an error within the abstract. (better with estradiol) was written instead of (better with estriol). The error has been corrected for this version.